- Home
- INVA vs GLPG Comparison
INVA vs GLPG Comparison
Compare INVA & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVA | GLPG |
|---|---|---|
| Founded | 1996 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | 704 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | INVA | GLPG |
|---|---|---|
| Price | $22.83 | $28.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $32.80 | ★ $36.50 |
| AVG Volume (30 Days) | ★ 546.0K | 152.9K |
| Earning Date | 05-06-2026 | 04-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 816.67 | N/A |
| EPS | ★ 3.30 | N/A |
| Revenue | ★ $217,217,000.00 | N/A |
| Revenue This Year | $8.95 | N/A |
| Revenue Next Year | $12.65 | N/A |
| P/E Ratio | $6.87 | ★ N/A |
| Revenue Growth | ★ 62.63 | N/A |
| 52 Week Low | $16.52 | $22.59 |
| 52 Week High | $25.15 | $37.78 |
Technical Indicators
Market Signals| Indicator | INVA | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 58.70 | 29.99 |
| Support Level | $20.56 | $28.78 |
| Resistance Level | $25.15 | $29.28 |
| Average True Range (ATR) | 0.50 | 0.78 |
| MACD | 0.04 | -0.37 |
| Stochastic Oscillator | 75.00 | 2.13 |
Price Performance
Historical ComparisonAbout INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.